The effect of using chondroitin sulfate in osteoarthritis of the knee
DOI:
https://doi.org/10.12775/JEHS.2023.13.02.034Keywords
Chondroitin sulfate, osteoarthritis, treatment, kneeAbstract
Introduction: Osteoarthritis is the most common disease of the musculoskeletal system. It develops in the regulation of the quality and quantity of articular cartilage, which cushions the joint and improves the sliding of the articular surfaces. Chondroitin sulfate being a natural glycosaminoglycan is found in the cartilage and extracellular matrix. The European League Against Rheumatism (EULAR) recommends the use of chondroitin sulfate in the treatment of knee osteoarthritis.
Objective: The purpose of our study was to present, based on the available literature, the latest reports on the effect of chondroitin sulfate in knee osteoarthritis
Methods and materials: The present study was based on available data collected in the PubMed database and published between 2001 and 2022. The study was conducted by reviewing keywords such as: ,,knee osteoarthritis”, ,,chondroitin sulfate”, ,,treatment” ,,diagnosis”
State of knowledge: Joint cartilage is mainly composed of type II collagen, proteoglycans, chondrocytes and water. In healthy articular cartilage, the balance between the individual components is constantly maintained, thanks to which cartilage degradation is accompanied by its synthesis. The reviewed scientific papers evaluated the effect of chondroitin sulfate on pain in osteoarthritis.
Summary: We found a large inconsistency between experimental protocols and study results. Therefore, comparing publications evaluating the actual effect of chondroitin sulfate on joint synovial tissues and biochemical markers is challenging. Additional studies are needed focusing on long-term treatment as well as evaluating their potential disease modifying effects.
References
M. Hiligsmann et al., “Health economics in the field of osteoarthritis: An Expert’s consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO),” Semin Arthritis Rheum, vol. 43, no. 3, pp. 303–313, Dec. 2013, doi: 10.1016/j.semarthrit.2013.07.003.
O. Bruyère et al., “An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO),” Semin Arthritis Rheum, vol. 49, no. 3, pp. 337–350, Dec. 2019, doi: 10.1016/j.semarthrit.2019.04.008.
J. A. Kanis, C. Cooper, R. Rizzoli, and J.-Y. Reginster, “European guidance for the diagnosis and management of osteoporosis in postmenopausal women,” Osteoporosis International, vol. 30, no. 1, pp. 3–44, Jan. 2019, doi: 10.1007/s00198-018-4704-5.
H. Ma, W. Zhang, J. Shi, D. Zhou, and J. Wang, “The efficacy and safety of extracorporeal shockwave therapy in knee osteoarthritis: A systematic review and meta-analysis,” International Journal of Surgery, vol. 75, pp. 24–34, Mar. 2020, doi: 10.1016/j.ijsu.2020.01.017.
K. D. Allen, “Cost-effectiveness of physical activity and exercise therapy programs for knee osteoarthritis: making the case for health plan coverage,” Osteoarthritis Cartilage, vol. 28, no. 6, pp. 719–720, Jun. 2020, doi: 10.1016/j.joca.2020.02.833.
A. M. T. Lubis, C. Siagian, E. Wonggokusuma, A. F. Marsetyo, and B. Setyohadi, “Comparison of Glucosamine-Chondroitin Sulfate with and without Methylsulfonylmethane in Grade I-II Knee Osteoarthritis: A Double Blind Randomized Controlled Trial.,” Acta Med Indones, vol. 49, no. 2, pp. 105–111, Apr. 2017.
M. Simental-Mendía, A. Sánchez-García, F. Vilchez-Cavazos, C. A. Acosta-Olivo, V. M. Peña-Martínez, and L. E. Simental-Mendía, “Effect of glucosamine and chondroitin sulfate in symptomatic knee osteoarthritis: a systematic review and meta-analysis of randomized placebo-controlled trials,” Rheumatol Int, vol. 38, no. 8, pp. 1413–1428, Aug. 2018, doi: 10.1007/s00296-018-4077-2.
B. R. da Costa et al., “Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis,” The Lancet, vol. 390, no. 10090, pp. e21–e33, Jul. 2017, doi: 10.1016/S0140-6736(17)31744-0.
C. Beaudart et al., “Symptomatic Efficacy of Pharmacological Treatments for Knee Osteoarthritis: A Systematic Review and a Network Meta-Analysis with a 6-Month Time Horizon,” Drugs, vol. 80, no. 18. Adis, pp. 1947–1959, Dec. 01, 2020. doi: 10.1007/s40265-020-01423-8.
M. Bishnoi, A. Jain, P. Hurkat, and S. K. Jain, “Chondroitin sulphate: a focus on osteoarthritis,” Glycoconjugate Journal, vol. 33, no. 5. Springer New York LLC, pp. 693–705, Oct. 01, 2016. doi: 10.1007/s10719-016-9665-3.
D. O. Clegg et al., “Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis,” New England Journal of Medicine, vol. 354, no. 8, pp. 795–808, Feb. 2006, doi: 10.1056/NEJMoa052771.
D. Sanghi et al., “Does Vitamin D Improve Osteoarthritis of the Knee: A Randomized Controlled Pilot Trial,” Clin Orthop Relat Res, vol. 471, no. 11, pp. 3556–3562, Nov. 2013, doi: 10.1007/s11999-013-3201-6.
A. E. Denoble et al., “Uric acid is a danger signal of increasing risk for osteoarthritis through inflammasome activation,” Proceedings of the National Academy of Sciences, vol. 108, no. 5, pp. 2088–2093, Feb. 2011, doi: 10.1073/pnas.1012743108.
G. Honvo, O. Bruyère, and J.-Y. Reginster, “Update on the role of pharmaceutical-grade chondroitin sulfate in the symptomatic management of knee osteoarthritis,” Aging Clin Exp Res, vol. 31, no. 8, pp. 1163–1167, Aug. 2019, doi: 10.1007/s40520-019-01253-z.
G. Sobal, R. Dorotka, J. Menzel, and H. Sinzinger, “Uptake studies with chondrotropic 99mTc-chondroitin sulfate in articular cartilage. Implications for imaging osteoarthritis in the knee,” Nucl Med Biol, vol. 40, no. 8, pp. 1013–1017, Nov. 2013, doi: 10.1016/j.nucmedbio.2013.07.007.
B. Hutton et al., “The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations,” Ann Intern Med, vol. 162, no. 11, pp. 777–784, Jun. 2015, doi: 10.7326/M14-2385.
X. Jin et al., “Effect of Vitamin D Supplementation on Tibial Cartilage Volume and Knee Pain Among Patients With Symptomatic Knee Osteoarthritis,” JAMA, vol. 315, no. 10, p. 1005, Mar. 2016, doi: 10.1001/jama.2016.1961.
M. C. Hochberg et al., “American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee,” Arthritis Care Res (Hoboken), vol. 64, no. 4, pp. 465–474, Apr. 2012, doi: 10.1002/acr.21596.
Q. Wang et al., “Identification of a central role for complement in osteoarthritis,” Nat Med, vol. 17, no. 12, pp. 1674–1679, Dec. 2011, doi: 10.1038/nm.2543.
S. Safiri et al., “Global, regional, and national burden of neck pain in the general population, 1990-2017: systematic analysis of the Global Burden of Disease Study 2017,” BMJ, p. m791, Mar. 2020, doi: 10.1136/bmj.m791.
T. Vos et al., “Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015,” The Lancet, vol. 388, no. 10053, pp. 1545–1602, Oct. 2016, doi: 10.1016/S0140-6736(16)31678-6.
B. Zinman et al., “Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes,” New England Journal of Medicine, vol. 373, no. 22, pp. 2117–2128, Nov. 2015, doi: 10.1056/NEJMoa1504720.
S. Fernández-Martín, A. González-Cantalapiedra, F. Muñoz, M. García-González, M. Permuy, and M. López-Peña, “Glucosamine and Chondroitin Sulfate: Is There Any Scientific Evidence for Their Effectiveness as Disease-Modifying Drugs in Knee Osteoarthritis Preclinical Studies?—A Systematic Review from 2000 to 2021,” Animals, vol. 11, no. 6, p. 1608, May 2021, doi: 10.3390/ani11061608.
C. Beaudart et al., “Quality of life assessment in musculo-skeletal health,” Aging Clin Exp Res, vol. 30, no. 5, pp. 413–418, May 2018, doi: 10.1007/s40520-017-0794-8.
J. J. Willeumier, C. W. P. G. van der Wal, R. J. P. van der Wal, P. D. S. Dijkstra, and M. A. J. van de Sande, “Stop, Think, Stage, Then Act,” in Management of Bone Metastases, Cham: Springer International Publishing, 2019, pp. 213–224. doi: 10.1007/978-3-319-73485-9_20.
P. Bourgeois, G. Chales, J. Dehais, B. Delcambre, J.-L. Kuntz, and S. Rozenberg, “Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3×400 mg/day vs placebo,” Osteoarthritis Cartilage, vol. 6, pp. 25–30, May 1998, doi: 10.1016/S1063-4584(98)80008-3.
L. Bucsi and G. Poór, “Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis,” Osteoarthritis Cartilage, vol. 6, pp. 31–36, May 1998, doi: 10.1016/S1063-4584(98)80009-5.
B. Mazieres, B. Combe, A. Phan Van, J. Tondut, and M. Grynfeltt, “Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study.,” J Rheumatol, vol. 28, no. 1, pp. 173–81, Jan. 2001.
P. Morreale, R. Manopulo, M. Galati, L. Boccanera, G. Saponati, and L. Bocchi, “Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis.,” J Rheumatol, vol. 23, no. 8, pp. 1385–91, Aug. 1996.
A. D. Sawitzke et al., “Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT,” Ann Rheum Dis, vol. 69, no. 8, pp. 1459–1464, Aug. 2010, doi: 10.1136/ard.2009.120469.
D. Uebelhart et al., “Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo11Principal Investigators: D. Uebelhart, MD, Assistant Professor; M. Malaise, MD, Professor, R. Marcolongo, MD, Professor; E. Vignon, MD, Professor. Co-Investigators: M. Piperno, MD, Head Physician; E. Mailleux, MD, Head Physician; A. Fioravanti, MD, Head Physician; L. Matoso, MD, Physician; Statistical analysis: F. DeVathaire, PhD, Professor;,” Osteoarthritis Cartilage, vol. 12, no. 4, pp. 269–276, Apr. 2004, doi: 10.1016/j.joca.2004.01.004.
D. Uebelhart, E. J.-M. A. Thonar, P. D. Delmas, A. Chantraine, and E. Vignon, “Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study,” Osteoarthritis Cartilage, vol. 6, pp. 39–46, May 1998, doi: 10.1016/S1063-4584(98)80011-3.
L. M. Wildi et al., “Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI,” Ann Rheum Dis, vol. 70, no. 6, pp. 982–989, Jun. 2011, doi: 10.1136/ard.2010.140848.
J.-J. Railhac, M. Zaim, A.-S. Saurel, J. Vial, and B. Fournie, “Effect of 12 months treatment with chondroitin sulfate on cartilage volume in knee osteoarthritis patients: a randomized, double-blind, placebo-controlled pilot study using MRI,” Clin Rheumatol, vol. 31, no. 9, pp. 1347–1357, Sep. 2012, doi: 10.1007/s10067-012-2022-4.
B. Zegels, P. Crozes, D. Uebelhart, O. Bruyère, and J. Y. Reginster, “Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study,” Osteoarthritis Cartilage, vol. 21, no. 1, pp. 22–27, Jan. 2013, doi: 10.1016/j.joca.2012.09.017.
P. Bourgeois, G. Chales, J. Dehais, B. Delcambre, J.-L. Kuntz, and S. Rozenberg, “Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3×400 mg/day vs placebo,” Osteoarthritis Cartilage, vol. 6, pp. 25–30, May 1998, doi: 10.1016/S1063-4584(98)80008-3.
L. Bucsi and G. Poór, “Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis,” Osteoarthritis Cartilage, vol. 6, pp. 31–36, May 1998, doi: 10.1016/S1063-4584(98)80009-5.
J. A. Singh, S. Noorbaloochi, R. MacDonald, and L. J. Maxwell, “Chondroitin for osteoarthritis,” Cochrane Database of Systematic Reviews, vol. 2016, no. 4, Jan. 2015, doi: 10.1002/14651858.CD005614.pub2.
S. Fernández-Martín, A. González-Cantalapiedra, F. Muñoz, M. García-González, M. Permuy, and M. López-Peña, “Glucosamine and Chondroitin Sulfate: Is There Any Scientific Evidence for Their Effectiveness as Disease-Modifying Drugs in Knee Osteoarthritis Preclinical Studies?—A Systematic Review from 2000 to 2021,” Animals, vol. 11, no. 6, p. 1608, May 2021, doi: 10.3390/ani11061608.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Ziemowit Żaba, Aleksandra Lisowska, Wojciech Żołyniak, Paweł Warzyszak, Róża Małek, Maria Milczek, Izabela Hawranik, Mikołaj Tomasik, Szymon Niski, Mateusz Skrzypek
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 415
Number of citations: 0
